Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atuzaginstat - Quince Therapeutics

Next Previous
X
Search
Drug Profile

Atuzaginstat - Quince Therapeutics

Alternative Names: COR-388; COR388-HCl

Latest Information Update: 31 Jan 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cortexyme
  • Developer Quince Therapeutics
  • Class Anti-inflammatories; Antibacterials; Antidementias; Antineoplastics; Antiparkinsonians; Neuroprotectants; Small molecules
  • Mechanism of Action Peptide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Alzheimer's disease
  • Phase II Periodontal disorders
  • Preclinical Parkinson's disease; Squamous cell cancer

Most Recent Events

  • 27 Jan 2023 COR 388 licensed to Lighthouse Pharmaceuticals in the US
  • 01 Aug 2022 Atuzaginstat is available for licensing as of 01 Aug 2022. www.quincetx.com
  • 01 Aug 2022 Cortexyme is now called Quince Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top